Method of purulent pleuropulmonary cavity treatment

FIELD: medicine.

SUBSTANCE: thoracocentesis is performed followed by cavity flushing with aseptic solution and active aspiration. Further sanitated pleuropulmonary cavity is filled by 1/3 of its volume by antiseptic fluid including 1.7 ml of 33% hydrogen peroxide solution, 0.8 ml of 85% formic acid solution and up to 100 ml of glycerin. Then this solution is exposed until overflow feeling appears, and fluid volume accumulated in pleuropulmonary cavity is removed.

EFFECT: accelerated removal of necrotic areas and pus from purulent pleuropulmonary cavity without side effects and complications due to multidirectional effect of the solution components.

2 ex

 

The invention relates to a purulent surgery and can be used in the treatment of purulent plavalaguna cavities.

There is a method of treatment of purulent plavalaguna cavities (USSR Author's certificate No. 16836969, IPC AV 17/00, AK 31/00, 1991), including thoracocentesis, sanitation and exposure in the field of antiseptic liquid, then sanitized in the cavity is injected glycerol in the amount of 1/3 of the cavity and the exposure it will continue until the feelings of fullness, and then the cavity was washed with aseptic solution with active aspiration.

The disadvantage of this method is that the treatment can be applied to the patient several times, when there is a danger of leakage of the contents of the cavity in the soft tissue of the chest wall along the drainage channel and, therefore, there are side effects and complications, which leads to low efficiency of treatment when using one of glycerin.

The task of the claimed method of treatment of purulent plavalaguna cavities is to increase the effectiveness of treatment due to the rapid purification of the cavity from necrotic areas and pus in the absence of side effects and complications.

This object is achieved by a method for the treatment of purulent plavalaguna cavities, which includes thoracocentesis, sanitation and exposure to oral antiseptic liquid, when et is m antiseptic liquid, composed of glycerol, 33% solution of hydrogen peroxide and 85% solution of formic acid, in the following ratio of components:

33% solution of hydrogen peroxide 1.7 ml;

85% formic acid, 0.8 ml;

glycerin and 100 ml,

then the above composition is administered in a sanitized cavity in the amount of 1/3 of the cavity and the exposure it will continue until the feelings of fullness, and then carry out the evacuation accumulated in plavalaguna oral liquid mass, then the cavity was washed with aseptic solution with active aspiration.

Distinctive features of the prototype is that the antiseptic liquid, composed of glycerol, 33% solution of hydrogen peroxide and 85% solution of formic acid, in the following ratio of components:

33% solution of hydrogen peroxide 1.7 ml;

85% formic acid, 0.8 ml;

glycerin to 100 ml.

The method is as follows.

The patient under local anesthesia perform thoracocentesis with drainage of the cavity, and then perform the initial evacuation of purulent-necrotic mass. After that, the pleural cavity or abscess cavity through the drainage tube filled with sterile antiseptic liquid (glycerin, 33% solution of hydrogen peroxide and 85% formic acid) in the amount equal to 1/3 of the volume of the cavity, the clamp pinch drainage t the pipe, the exhibition continues until a feeling of fullness (there is a danger of leakage of the contents of the cavity in the soft tissue of the chest wall along the drainage channel).

Then carry out the evacuation accumulated in the pleural cavity of the liquid mass, and then washed with a 2% solution of bicarbonate of soda or furatsilinom 1:5000. In accordance with the characteristics and dynamics of the content of a purulent cavity at the final stage of rehabilitation possible active aspiration and lavage content purulent cavity fluids, antibiotics and antiseptics. Depending on the severity of purulent cavity treatment can be applied to the patient several times.

Glycerol forms in the pleural cavity triglycerides of higher fatty acids with stimulating property for tissue regeneration. In addition to the qualities of the solvent glycerin causes hyperemia surrounding tissue, dehydration and lysis of neutrophilic leukocytes. Lysis of cells leads to the release of lysozyme and peroxidase with their high antibacterial properties, accompanied by the local fibrinolysis, has linimentum action and has a positive effect on any inflammatory process.

Formic acid improves tissue metabolism - local irritation, local anasthesiologie has protivovospalitelnoe distracting effect. Stimulates the formation and release of enkephalins and neuropeptides that regulate pain and vascular permeability. Stimulates delayed liberation of histamine, kinins, and other biologically active compounds, dilates blood vessels, stimulating the immunological processes that affect blood clotting.

Hydrogen peroxide antiseptic, hemostatic, antiseptic, deodorizing action. Antiseptic due to oxidant effect when in contact with the damaged mucosa of hydrogen peroxide under the influence of catalase and peroxidase decomposes into oxygen, including active forms, which creates unfavorable conditions for the growth of microorganisms, especially putrefactive anaerobic forms. When she enters the solution in the cavity is the destruction (oxidation) of proteins, blood, pus, and its mechanical cleansing by rich foam, in addition, promotes blood clots and stop bleeding from small vessels, which is important in extensive lung abscesses.

The solution is prepared as follows: 33% solution of hydrogen peroxide - 1.7 ml; 85% formic acid and 0.8 ml glycerol 100 ml mixed in a glass vessel, the vessel is then placed in cold water for 1-1 .5 hours or place in the refrigerator for 1 hour. Then GE is prepared solution can be applied. Store the solution you need in a glass jar with hermetic lid in a cool place. The solution has no side effects and is completely harmless.

The proposed method is tested on 25 patients with abscesses and pleural empyema.

Example 1.

Patient Y. 53 years was admitted to the hospital with a diagnosis of pyopneumothorax right, empyema right. Thoracocentesis right from the pleural cavity were estimated to be approximately 800 ml of pus, then put about 100 ml of solution, the exposure continues until a feeling of fullness in the follow-through day 80, 60, 40 ml, etc. After 12 days on the control radiograph of the right lung is fully expanded. The drain was removed on day 16.

Example 2.

Patient C. - 46 years was admitted to the hospital with a diagnosis of empyema on the right. Treatment in the Central district hospital for 2 months with no effect. Upon receipt conducted thoracocentesis with drainage, were estimated to be approximately 650 ml of pus, and then introduced into the cavity of about 80 ml, the exhibition continues until a feeling of fullness in the subsequent 60, 40, 20 ml 7 days after treatment the x-ray light expanded, fluid in the pleural cavity no. The normal temperature from the third day. On day 10 drainage deleted.

When the treatment by the proposed method purulent cavity easy to clean, easy raspy what is improves the condition of the patient, after two or three treatments reduced temperature, improved sleep, appetite, and the patient recovers much earlier than those patients who were treated according to traditional methods. The method recommended for use in purulent surgery.

The method of treatment of purulent plavalaguna cavities, including thoracocentesis, sanitation and exposure to oral antiseptic liquid, and then the cavity was washed with aseptic solution with active aspiration, characterized in that the antiseptic liquid, composed of glycerol, 33%solution of hydrogen peroxide and a 85%aqueous solution of formic acid in the following ratio of components:

33%solution of hydrogen peroxide 1.7 ml;

85%formic acid, 0.8 ml;

glycerin and 100 ml,

then the above composition is administered in a sanitized cavity in the amount of 1/3 of the cavity and the exposure it will continue until the feelings of fullness, and then carry out the evacuation accumulated in plavalaguna oral liquid mass.



 

Same patents:

FIELD: medicine; otorhinolaryngology.

SUBSTANCE: spend puncture and lavage of the damaged nasal sinus of 0.9% solution of Sodium chloridum to pure washing waters. Then enter a microirrigator, perform aeration of sinus and enter 5 ml of 5% Mexidol. Further spend repeated lavages of a sinus with aeration and introduction of Mexidol. Daily, since the second day of treatment, estimate mucociliary transport of a mucosa of a nasal cavity from lesion. At achievement of the mucociliary clearance of 26.35±2.13 mm for 15 minutes, stop treatment.

EFFECT: restriction of membranodestruction action of inflammatory process on mucosa and fast restoration of function of ciliary epithelium, rising of efficiency of treatment and prevention of transition of inflammatory process in the chronic form.

2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: water pharmaceutical solution contains oxymetazoline and/or xylomethazolinum, salt of zinc and buffer salt and its applications for local introduction in nose for putting off of edema of mucosa.

EFFECT: increased stability, reduction of hydrolysis of active substances in the presence of zinc salt.

17 cl, 8 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: novel derivatives of 4-phenyltetrahydroisoquinolines have total formula I: , in which R1, R2, R3 and R4 independently on each other represent H, F, CI, Br, I, alkyl with 1, 2, 3 or 4 C-atoms; R5 represents H, alkyl with 1, 2, 3 or 4 C-atoms; R6 represents H, alkyl with 1, 2, 3 or 4 C-atoms; R7, R8 and R9 independently on each other represent H, COOR60, -L-G; R60 represents H, alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms; L represents -NR30CO-, -CONR30-, -NR30CONR31-, -NR30COO-; and R30 and R31 independently on each other represent H; G represents groups Ca(OR32)xH2a+1-x, and one or more CH2-groups can be substituted with O; Cb(OR32)yH2b-1-y,and one or more CH2-groups can be substituted with O; CcH2c+1 and two or more CH2- groups can be substituted with O; -(CH2)z-COOR34, where atom of H group -(CH2)z - can be substituted with group OR32; -CR38R39-COOR40, -(CH2)Z-SO3R34; -(CH2)z-N+R35R36R37; -CR38R39NR41R42; a is equal 2, 3, 4, 5 or 6; x is equal 2, 3, 4, or 5 R32 represents H; b is equal 6; y is equal 4; c is equal 5; z is equal 1 or 2; R34, R35, R36 and R37 independently on each other represent H or alkyl with 1, 2, 3, 4, 5 or 6 C-atoms; R38 represents -(CH2)n-Y; n is equal 1 or 3; Y represents H, -COOR44, -CONR45R46, -NHC(NH)NH2, imidazole -4-yl; R44, R45 and R46 independently on each other represent H; R39 represents H; R40 represents H, alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms; R41 and R42 independently on each other represent H; and, at least, one of residues of R7, R8 or R9 must represent group -L-G, as well as their pharmaceutically acceptable salts and salts of trifluoroacetic acid. Invention also relates to medication and its application for treatment and prevention of number of diseases.

EFFECT: novel derivatives of 4-phenyltetrahydroisoquinalines, which have inhibiting effect on NHE3.

14 cl, 2 tbl, 47 ex

FIELD: medicine; pharmacology.

SUBSTANCE: compound for washing of a nasal cavity, nasopharynx and an oral cavity includes salt rock, carnallite, baking soda, a dry extract of dogrose and a dry licorice extract at the following parity of components, wt %: salt rock 70.0; carnallite 25.0; baking soda 2.0; a dry extract of dogrose 1.5; a dry licorice extract - 1.5.

EFFECT: improvement mucous nasopharynxes nutrition and absence of an insoluble deposit.

FIELD: medicine, pulmonology.

SUBSTANCE: thermotherapy is carried out. Naphtalane applications with temperature of 41°-42°C and weight of 150-200 g are used as a heat carrier. Applications are applied over the projection region of lungs' roots and place of localisation of inflammatory tissue. Exposure duration is 15-20 minutes. The procedure is carried out within 5 straight days with the rest of 2-3 days. The course consists of 12-15 procedures.

EFFECT: apparent anti-inflammatory, mucolytic, immunocorrective, analgesic, reparative effects, decrease of taking the medicines, prevention of undesired collateral effects, time decrease of treatment, ensuring of partial structural and functional restoration of pulmonary tissues, clinico-functional parameters, can be used in treatment of patients with coexistent diseases.

2 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: described are novel pyridopyrrolizine and pyridoindolizine derivatives of general formula I and their pharmaceutically acceptable salts and hydrates, where A is C1-3alkyl; Ar stands for naphtyl or phenyl optionally substituted with one or two groups, selected from halogen, C1-6alkyl or C1-6alkyl haloid; Q stands for COOH; one of X1, X2, X3 or X4 stands for nitrogen, others are independently selected from CH and C-Rg, where Rg stands for C1-6alkyl or S(O)nC1-6alkyl, where n=0, 2; Y1 stands for S or C(O); Y2 stands for (CRdRe)m, where Rd and Re - hydrogen, m is integer 1 or 2; R1, R2, R3 stands for hydrogen, pharmaceutical composition, containing them, and method of treatment of diseases, mediated by prostaglandin D2.

EFFECT: obtaining novel pyridopyrrolizine and pyridoindolizine derivatives which possess useful properties.

22 cl, 2 tbl, 17 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: invention relates to novel compounds of formula (I), its pharmaceutically acceptable salts, possessing qualities of chemokine receptor modulators. Compounds can be applied for asthma, allergic rhinitis, COLD, inflammatory intestinal disease, irritated intestine syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer. In compound of formula (I) , R1 represents group selected from C1-8alkyl, said group is possibly substituted with 1, 2 or 3 substituents, independently selected from -OR4 , -NR5R6 , phenyl, phenyl is possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR4,-NR5R6,-SR10,C1-6alkyl and trifluoromethyl; R2 represents group selected from C1-8alkyl, said group is substituted with 1, 2 or 3 substituents, independently selected from hydroxy, amino, C1-6alkoxy, C1-6alkylamino, di(C1-6alkyl)amino, N-(C1-6alkyl)-N-(phenyl)amino; R3 represents hydrogen, R4 represents hydrogen or group selected from C1-6alkyl and phenyl, R5 and R6, independently, represent hydrogen or group selected from C1-6alkyl and phenyl, said group being probably substituted with 1, 2 or 3 substituents, independently selected from -OR14, -NR15R16, -COOR14,-CONR15R16, or R5 and R6 together with nitrogen atom, to which they are bound, form 4-7-member saturated heterocyclic ring system, possibly containing additional heteroatom, selected from oxygen and nitrogen atoms, ring possibly being substituted with 1, 2 or 3 substituents, independently selected from -OR14, -COOR14,-NR15R16,CONR15R16 and C1-6alkyl; R10 represents hydrogen or group selected from C1-6alkyl or phenyl; and each from R7, R8, R9, R14, R15, R16 independently represents hydrogen, C1-6alkyl or phenyl; X represents hydrogen, halogeno; Rx represents trifluoromethyl, -NR5 R6 , phenyl, naphtyl, heteroaryl, heteroring can be partly or fully saturated, and one or more ring carbon atoms can form carbonyl group, each phenyl or heteroaryl group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, cyano, -OR4, -NR5R6, -CONR5R6, -COR7, -COOR7, -NR8COR9, -SR10, -SO2R10, -SO2NR5R6, -NR8SO2R9, C1-6alkyl or trifluoromethyl; or Rx represents group selected from C1-6alkyl, said group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR4, -NR5R6, phenyl or heteroaryl, where heteroaryl represents monocyclic or bicyclic aryl ring, containing from 5 to 10 ring atoms, from which 1, 2 or 3 ring atoms are selected from nitrogen, sulfur or oxygen. Invention also relates to methods of obtaining compounds, versions, pharmaceutical composition and application for manufacturing medications using compounds of invention.

EFFECT: obtaining novel compounds of formula (I), its pharmaceutically acceptable salts, possessing properties of chemokine receptor moduators.

25 cl, 138 ex

FIELD: medicine; surgery.

SUBSTANCE: in preoperative preparation period and in early postoperative period zinc sulphate inhalations are additionally conducted. One inhalation procedure takes 10 to 15 mg as calculated to elemental zinc. Procedures are conducted daily during 7 to 10 days before and 7 to 10 days after the operation.

EFFECT: reducing cure period, inflammatory reactions preventing in bronchial tree.

3 ex

FIELD: medicine; pharmacology.

SUBSTANCE: in formula (I) V represents -N (R1) (R2) or OR4; R4 represents H, C1-6alkyl, C1-6halogenalkyl or (C1-6alkylen)0-1R4' R4' represents C3-7cycloalkyl, phenyl, pyridyl, piperidinyl; and R4' is optionally substituted with 1 or 2 identical or different substitutes chosen from group consisting of C1-4alkyl, amino, C1-3alkylamino, C1-3dialkylamino, phenyl and benzyl; and each R1 and R2 independently represents L1, where L1 is chosen from group consisting from H, C1-6alkyl, C2-6alkenyl, C2-6alkinyl, - adamantyl, pyrrolidinyl, pyridyl, or R1 and R2 together with nitrogen atom to which attached, form X, where X represents pyrrolidinyl, piperazinyl, piperidinyl, morpholino; where X is optionally substituted with Y, where Y represents dioxolanyl, C1-9alkyl, phenyl, furanyl, pyrrolyl, pyridyl, pyrrolidinyl; and where X and Y are optionally split with Z, where Z represents -C1-3alkylen-, C1-3alkylen-. Other radical values are specified in formula of invention.

EFFECT: effective application for treatment of migraine and other headache mediated by action of CGRP-receptors.

34 cl, 11 dwg, 6 tbl, 201 ex

FIELD: medicine; pharmacology.

SUBSTANCE: in formula (I) V represents -N (R1) (R2) or OR4; R4 represents H, C1-6alkyl, C1-6halogenalkyl or (C1-6alkylen)0-1R4' R4' represents C3-7cycloalkyl, phenyl, pyridyl, piperidinyl; and R4' is optionally substituted with 1 or 2 identical or different substitutes chosen from group consisting of C1-4alkyl, amino, C1-3alkylamino, C1-3dialkylamino, phenyl and benzyl; and each R1 and R2 independently represents L1, where L1 is chosen from group consisting from H, C1-6alkyl, C2-6alkenyl, C2-6alkinyl, - adamantyl, pyrrolidinyl, pyridyl, or R1 and R2 together with nitrogen atom to which attached, form X, where X represents pyrrolidinyl, piperazinyl, piperidinyl, morpholino; where X is optionally substituted with Y, where Y represents dioxolanyl, C1-9alkyl, phenyl, furanyl, pyrrolyl, pyridyl, pyrrolidinyl; and where X and Y are optionally split with Z, where Z represents -C1-3alkylen-, C1-3alkylen-. Other radical values are specified in formula of invention.

EFFECT: effective application for treatment of migraine and other headache mediated by action of CGRP-receptors.

34 cl, 11 dwg, 6 tbl, 201 ex

FIELD: medical equipment.

SUBSTANCE: nonsuction triple-lumen drainage tube contains bed made of silicone drainage tube perforated at blind-ended points and accommodating two capillary channels from full-length tube wall that are separated with diaphragm from the main lumen. The gate of one capillary channel opens outward at top of blind-ended point. The gate of other capillary channel opens at top in the basic gleam of a tube.

EFFECT: improved lifetime sanation and drainage of drainage tube due to possibility to eliminate tissue suction and simplify declogging of the main lumen of the tube.

4 dwg

FIELD: medicine; surgery.

SUBSTANCE: after the median laparotomy, liquidation of peritonitis source and primary sanation of abdominal cavity, mini-abdominal sections at 3-4 cm length are carried out on both left and right anterolateral and frontal abdominal wall. Flat drainages at width of 3-4 xm are put into mini-laparotomy cuts. The median laparotomy wound is covered by layers with napkins, separating purulent wound edges from abdominal cavity and leaving the abdominal cavity opened in the form of laparostoma. Scheduled sanations of the abdominal cavity through median laparotomy wound are carried out before the purification of its edges and decrease of intraabdominal hypertensia. Then a median wound is sutured in layers. The further sanations are carried out separately in abdominal cavity areas through mini-laparotomy cuts. In case of peritonitis and purulent liquidation in one of the areas the sanation is stopped. Sanitation of other areas is continued. Drainages are left before the termination of serous contents discharge from the abdominal cavity.

EFFECT: primary adhesion of median wound, decrease of sanations traumatism and increase of their efficiency, improvement of abdominal cavity drainage, acceleration of peritonitis liquidation.

2 cl, 2 ex

FIELD: medicine; surgery.

SUBSTANCE: device for long selective controlled collapse of a lung contains the tubular case with the internal channel. The cylinder fanned by air is tightly fixed near the extremity of the channel. The additional channel is executed in the tubular case. The additional channel is located in the tubular case and tightly separated from its internal channel. The aperture is executed in a wall of the tubular case. The aperture connects the cylinder cavity to the additional channel which is deduced on an external wall of the tubular case and is bridged to the valve through the demountable adapter. Through apertures for air and exsudate excision are executed outside of the fanned cylinder in a wall of the tubular case. Necessary degree (volume) of a selective and controlled collapse of the lung damaged with tuberculosis, with achievement of the dosed out prelum (fall) of a cavern, including fibrous and creations of conditions for its cicatrisation and the termination bacterioexcretion is provided; conditions for the prevention of the most frequent and dangerous pleuropulmonary complications (bleedings, curtailed hemothorax, spontaneous amotio of a lung up to a diaphragm, an insufficient and uncontrollable collapse of a lung and a cavern) are framed; the proof sterile extrapleural cavity, suitable for further it seal by the modern preparations entering into the general metabolism (collagen and analogues) and not demanding the further excision by performance of repeated operation is formed.

EFFECT: increase of efficiency and decrease of risk of complications.

4 cl

FIELD: medicine; surgery.

SUBSTANCE: within postoperative wound drainage bundled 5-10 capron ligatures going 10 cm beyond work end of standard tubular capillary suction drain and placed in retroperitoneal space are inserted to lumen of suction drain. External end of suction drain with ligatures are delivered from wound 5 cm away. Ligatures are impregnated with exudate, taken out one by one using tweezers and supplied to inoculation in bacteriological laboratory in standard sterile test tubes. Every time, after one ligature is removed, external end of suction drain with bunched ligatures is cut 1 mm off.

EFFECT: invention use allows for microflora monitoring in postoperative wound and paravasal space following reconstructive vascular operations with minimum outside infection of wound and painlessness of procedure.

1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: shunt contains silastic pomp mounted between two back valves and membrane. Valves are in the form of linear bushings with radial aperture d tighten inside due to tape bend. Ratio of valve capacity to pressure fall is proportional to value where δ is tape thickness, mm; d is valve aperture diameter, mm; b is tape width, mm; N is liquor rate (valve capacity), mm3/min; R is internal radius of bushing, mm; ΔP is pressure fall, mm WC. Linear bushings are simultaneously executed on flat foundation. The second bushing is segmental to the first one. There is a partition amounted from above between bushings. Bushings are end blocked from above by dome-shaped membrane of variable radius and variable thickness in dome point δp and along edges δe by relation δe/δp=1.3±0.1.

EFFECT: workable design with controlled parameters and minimised dimensions.

4 dwg

Drainage device // 2336912

FIELD: medicine.

SUBSTANCE: invention concerns medicine, in particular to surgery, and can be used in treatment of open wound cavities of soft tissues. The drainage device includes a capacity with antiseptic, capacity for the flushing water, supply tube connecting the antiseptic capacity with a wound cavity, outlet tube and an air tube, with one end connected to the capacity with the antiseptic. The mentioned air tube is connected by other end to the basis of a rubber bag on which the supply tube is established. On the end of the rubber bag the elastic tube which is established in the capacity for flushing water is fixed in such a manner that liquid level would close access of air to the tube.

EFFECT: provision of supply of the antiseptic solution in open wound cavity, and also constant active outflow of flushing water from the drained wound cavity.

2 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention is referred to medicine and can be used for an aspiration of contents of abdominal and pleural cavities. The device for evacuation of contents of abdominal and pleural cavities contains a metal tube with a carving on the distal end. The hollow capacity with apertures for collection of liquid and a mobile nut is placed on a carving. The hollow capacity has the cylindrical form, a face aperture and is located on a carving with possibility of moving for adjustment of volume and bracing by a nut. The technical result lies in simplicity of the device design and usage convenience.

EFFECT: creation of the simple and convenient device for evacuation of contents of abdominal and pleural cavities.

2 cl, 1 ex, 1 dwg

Drainage system // 2329833

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to surgery, and can be applied for through drainage of wounds or pathological cavities. Drainage system contains tube and rod by its width with sharp working end and handle on external end, thus tube is shorter than rod. Rod is equipped with the second tube. Tubes are joined by ends with lateral perforations. Rod consists of two detachable parts. Rod backside has external thread with nut mounted between handle and tube. Rod working end is supplied with cone-shaped cleavage with backside support point of diameter not less than external diameter of tube. Invention is aimed at reduction of tissue bacterial pollution hazard with drainage complication decrease by means of two drainage tubes simultaneously applied and removed without external end installation through tissues.

EFFECT: development of drainage system design applied for wounds or pathological cavities.

3 cl, 9 dwg

FIELD: medicine.

SUBSTANCE: device for sanation of the abdominal cavity consists of perforated plate, drainage system, constraint plate and base plate. The solid base plate is made of two polyvinylchloride layers with draining canals between them that end with irrigating drainages. In the base centre, the perforated plate is installed, which serves as the floor of the chamber for peritoneal fluid outflow, and which is connected to two drainages. The bringing chamber connected to the bringing drainage is installed along the chamber perimeter, for fluid outflow. Along the perimeter of the bringing chamber, two rows of the holding loops are made. The length and width of the perforated plate correspond to the outflow chamber size. The length of the bringing chamber is equal to that of the outflow chamber, and the width is 0.5-1.0 cm. The length of the base plate is 10.0-20.0 cm, the width is 7.0-16.0 cm. The height of the device is 1.0-5.0 cm.

EFFECT: device enables more efficient sanation.

11 cl, 3 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: revision and surgical inspection and d-bridement of abdominal cavity are performed. The right and left hepatic ducts with the intersection left in between are separated. The biliary ducts are explored. The drainage system is prepared during the surgery using the disposable system for intravenous infusion. For this purpose, the oval hole is cut 3 cm from the tube's proximal end. The 3 cm long tube with a slantwise cut distal end is sutured into the hole tracing the annular divergence of the left and right ducts. Then, the drainage system is inserted into biliary ducts so as the aslant cuts contact each other.

EFFECT: method enables external drainage of hepatic ducts in absence of hepaticocholedoch in generalised biliary peritonitis.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly, to pharmaceutical vaginal compositions for treatment or prevention of vaginal infections. Composition contains synergistic mixture of bioadhesive medicinal form of prolonged release which reduces value pH and includes peroxide in amount, sufficient to increase oxygen concentration without either vagina sterilisation or considerable destruction of normal required local vaginal flora. Invention also refers to method of treatment or prevention of vaginal infections, including vaginal introduction of pharmaceutical vaginal compositions in amount, sufficient to decrease pH and increase in oxygen concentration without either vagina sterilisations or considerable destruction of normal desirable local vaginal flora.

EFFECT: development of effective method of treatment and prevention of vaginal infections.

35 cl, 1 tbl, 1 ex

Up!